The Expression Profiling of Serum miR-92a, miR-134 and miR-375 in Acute Ischemic Stroke

Abstract

Aim: To investigate the expression profile and diagnostic potentials of serum miR-92a, 134, and 375 in acute ischemic stroke (AIS) patients. Materials & methods: Serum miRs-92a, 134, and 375 expression profiles were estimated by qRT-PCR for 70 AIS patients, age-matched with 25 control subjects. Their diagnostic potential was estimated by ROC analysis. Results: Down-expression of miR-92a and miR-375 was found (56; 96.5%; -1.86 ± 1.36; and 53; 91.4%; -1.63 ± 1.38, respectively), while miR-134 showed a predominant upregulation (46; 79.3%; 0.853 ± 1.34). The diagnostic accuracy was the highest for miR-92a and miR-375 (area under the curve = 0.9183 and 0.898, respectively), with greater specificity for miR-375 (Sp = 96%). Conclusion: Serum miR-92a and miR-375 could be promising early detective biomarkers of AIS.

Plain Language Summary

This study aimed to examine how miR-92a, 134, and 375 in acute ischemic stroke (AIS) patients were expressed and if they could be used to diagnose the disease. Hence, their expression profiles were assessed in the serum of 70 AIS patients and 25 controls. Results showed that miR-92a and miR-375 were downregulated, while miR-134 was mostly upregulated. miR-92a and miR-375 had the best diagnostic accuracy, but miR-375 was more specific. Therefore, miR-92a and miR-375 show promise as potential early AIS biomarkers.

Keywords:

• AIS
• biomarkers
• miR-134
• miR-375
• miR-92a
• miRNA

Author contributions

AT Salman was responsible for the practical work, formal analysis and drafted the manuscript. O Shaker was responsible for samples collection, clinical records, and the practical part of the manuscript. SS Elshaer was involved in the paper idea, practical work and revising the final manuscript. A Elshafei was responsible for research protocol setting, practical supervision, validation of data, final manuscript revision and submission.

Acknowledgments

The authors would like to express their gratitude to patients and molecular biology lab members, Faculty of Medicine, Cairo University for their great help during the practical part of the study

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Data sharing statement

The authors certify that this manuscript reports original clinical trial data. The data will not be made publicly available.